Completed PHASE3 INTERVENTIONAL NCT00193830

High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix

Sponsor: Tata Memorial Hospital

Conditions Cancer of Cervix Cancer of the Cervix Cervical Cancer Cervix Cancer

Interventions HIgh Dose Rate Vs Low DOse Rate Brachytherapy

Updated 5 times since 2017 Last updated: May 5, 2015 Started: May 31, 1996 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cancer of Cervix and Cancer of the Cervix and is currently completed. Tata Memorial Hospital leads this study, which shows 5 recorded versions since 1996 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tata Memorial Hospital

Data source: Tata Memorial Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mumbai, India